The 6 most recent market catalysts affecting $CELZ, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 75
Creative Medical Technology Says All Patients Enrolled And Treated Across ADAPT Trial Of Olastrocel In Chronic Lower Back Pain, Including FDA-Cleared Opioid Expansion Cohort; Trial Moves To Follow-Up And Phase 3 Planning
The completion of enrollment and treatment in the ADAPT trial for Olastrocel is a critical de-risking event for Creative Medical Technology. The inclusion of an FDA-cleared opioid …
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Creative Medical Tech shares are trading higher after the company announced it received Notice of Allowance from the United States Patent and Trademark Office for a U.S. patent application titled "Suppression of Diabetes Using Exosomes From Stem Cell Programmed Myeloid Cells"
The Notice of Allowance for a patent application, especially one with a specific and potentially groundbreaking therapeutic application like 'Suppression of Diabetes Using Exosomes…
Aug 6, 2026
Corporate Catalyst
Neutral
Impact 65
Creative Medical Receives Notice Of Allowance From USPTO For US Patent Application Titled Suppression Of Diabetes Using Exosomes From Stem Cell Programmed Myeloid Cells
Creative Medical Technology Holdings, Inc. has secured a Notice of Allowance for a crucial patent covering its MyeloCelz™ platform, a cell-free exosome technology aimed at treating…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
Creative Medical Technology shares are trading higher after the company announced it has received a Notice of Allowance for a US patent titled "SUPPRESSION OF DIABETES USING EXOSOMES FROM STEM CELL PROGRAMMED MYELOID CELLS".
This patent allowance is a significant positive catalyst for Creative Medical Technology (CELZ) as it validates their innovative approach to diabetes treatment using exosomes. The …
Aug 5, 2026
Corporate Catalyst
Neutral
Impact 65
Creative Medical Technologies Has Received A Notice Of Allowance For A U.S. Patent Titled "SUPPRESSION OF DIABETES USING EXOSOMES FROM STEM CELL PROGRAMMED MYELOID CELLS"
Creative Medical Technologies (CELZ) announced a Notice of Allowance for a U.S. patent titled 'SUPPRESSION OF DIABETES USING EXOSOMES FROM STEM CELL PROGRAMMED MYELOID CELLS.' This…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.